Neoadjuvant capecitabine plus docetaxel ± trastuzumab therapy for recently diagnosed breast cancer:: phase II results

被引：0
|
作者：
Tripathy, D.
Moisa, C.
Gluck, S.
机构：
[1] Univ Texas SW Med Ctr, Dallas, TX USA
[2] Roche Labs Inc, Nutley, NJ USA
[3] Univ Miami, Miami, FL 33152 USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2007年 / 106卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：S226 / S226
页数：1
相关论文
共 50 条
  • [31] Neoadjuvant treatment of stage II or III breast cancer with docetaxel and low dose capecitabine, with addition of trastuzumab for HER 2 amplified tumors
    Khan, Q. J.
    Sharma, P.
    Kimler, B. F.
    Baranda, J.
    Andersen, J. C.
    Klemp, J.
    Fabian, C. J.
    BREAST, 2007, 16 : S49 - S49
  • [32] Trastuzumab plus docetaxel with or without capecitabine in patients with HER2-positive advanced/metastatic breast cancer:: Primary efficacy results from a randomised phase II study (CHAT)
    Wardley, Andrew
    Anton-Torres, Antonio
    Pivot, Xavier
    Morales-Vasquez, Flavia
    Zetina, Luis
    Dias Gaui, Maria de Fatima
    Reyes, Douglas Otero
    Jassem, Jacek
    Bell, Richard
    ANNALS OF ONCOLOGY, 2006, 17
  • [33] A phase II trial of weekly docetaxel and trastuzumab in metastatic breast cancer
    Taran, A.
    Wollschlaeger, K.
    Bluemel, B.
    Kettner, E.
    Costa, S. D.
    Bischoff, J.
    EJC SUPPLEMENTS, 2008, 6 (07): : 179 - 180
  • [34] Preliminary results of a phase II study of neoadjuvant treatment with docetaxel (T), doxorubicin (A) and capecitabine (X) in locally advanced or inflammatory breast cancer.
    Manga, GP
    Méndez, M
    Palomero, MI
    Quibén, R
    Belón, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 91S - 91S
  • [35] S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial
    Yong Wha Moon
    Soohyeon Lee
    Byeong-Woo Park
    Eun-Kyung Kim
    Seung Il Kim
    Ja Seung Koo
    Seho Park
    Min Jung Kim
    Hyun Cheol Chung
    Joo-Hang Kim
    Joohyuk Sohn
    BMC Cancer, 13
  • [36] S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial
    Moon, Yong Wha
    Lee, Soohyeon
    Park, Byeong-Woo
    Kim, Eun-Kyung
    Kim, Seung Il
    Koo, Ja Seung
    Park, Seho
    Kim, Min Jung
    Chung, Hyun Cheol
    Kim, Joo-Hang
    Sohn, Joohyuk
    BMC CANCER, 2013, 13 : 1 - 7
  • [37] A randomized controlled Phase II trial of vinorelbine plus capecitabine versus docetaxel plus capecitabine in anthracycline-pretreated women with metastatic breast cancer
    Li, Shufen
    Meng, Wenjing
    Zhang, Jibo
    Xie, Xiaojuan
    Hao, Chunfang
    Jia, Yongsheng
    Tong, Zhongsheng
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2020, 16 (05) : 1069 - 1076
  • [38] Xeloda (capecitabine) plus docetaxel combination therapy in locally advanced/metastatic breast cancer: latest results.
    Vukelja, SJ
    Moiseyenko, V
    Leonard, R
    Conte, PF
    Garin, A
    McKendrick, J
    Possinger, K
    Turpin, FL
    Vandenberg, TA
    O'Shaughnessy, JA
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 269 - 269
  • [39] Docetaxel-modulated capecitabine in patients with metastatic breast cancer: Updated results of a phase II study
    Puglisi, Fabio
    Lombardi, Davide
    Mansutti, Mauro
    Minisini, Alessandro
    Zanetti, Martina
    Cardellino, Giovanni
    La Mura, Nicoletta
    Nigri, Paola
    Piga, Andrea
    Veronesi, Andrea
    ANNALS OF ONCOLOGY, 2005, 16 : 12 - 12
  • [40] Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer
    Burris, HA
    SEMINARS IN ONCOLOGY, 2001, 28 (01) : 38 - 44
12345